In a move that’s set to reshape the landscape of biotech innovation, Illumina Inc. announced Monday it will acquire proteomics pioneer SomaLogic from its parent, Standard BioTools, in a bold deal worth up to $425 million. The acquisition is expected to amplify Illumina’s reach in the proteomics market and drive its multiomics roadmap into overdrive.
The agreement includes $350 million in upfront cash, with an additional $75 million tied to near-term performance milestones and royalties, according to statements released by both companies.
A High-Tech Fusion: From Molecules to Markets
Headquartered in Boulder, Colorado, SomaLogic specializes in protein biomarker discovery and diagnostics. Its labs, offices, and manufacturing space are all part of the acquisition. The company’s sophisticated aptamer-based affinity proteomics platform will be folded into Illumina’s robust sequencing and software arsenal.
“This deal accelerates our vision,” said Illumina CEO Jacob Thaysen. “We’ve been working closely with SomaLogic for over three years. Together, we can supercharge the development of cutting-edge biomarker tools and disease profiling technologies.”
SomaLogic’s SomaScan Proteomics Assay, already integrated into Illumina’s next-generation sequencing (NGS) platforms through a 2021 co-development agreement, will now become a central part of Illumina’s offering — deepening the biotech giant’s play in the high-plex proteomics space.
